0001564590-15-004497.txt : 20150519 0001564590-15-004497.hdr.sgml : 20150519 20150519154700 ACCESSION NUMBER: 0001564590-15-004497 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150514 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20150519 DATE AS OF CHANGE: 20150519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 15876357 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_20150514.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 14, 2015

 

ADAMIS PHARMACEUTICALS CORPORATION

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-36242

 

82-0429727

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

 

11682 El Camino Real, Suite 300

San Diego, CA

 

 

 

 

92130

(Address of Principal Executive Offices)

 

 

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (858) 997-2400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d‑2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e‑4(c))

 

 


 

 

Item 5.07.   Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of the Company was held on May 14, 2015, at the Company’s headquarters at 11682 El Camino Real, Suite 300, San Diego, California  92130 at 1:00 p.m. local time.  The following proposals were submitted to and approved by the stockholders at the meeting:

1.Election of the five nominees to the board of directors:

 

Votes For

Votes Withheld

Votes Abstaining

Broker Non-Votes

Dennis J. Carlo, Ph.D.

4,663,876

46,462

 

5,420,186

Richard C. Williams

2,985,075

1,725,263

 

5,420,186

Robert B. Rothermel

2,985,074

1,725,264

 

5,420,186

David J. Marguglio

2,818,459

1,891,879

 

5,420,186

William C. Denby, III

2,981,075

1,729,263

 

5,420,186

 

 

 

 

 

2.Approval, on a nonbinding advisory basis, of the compensation of the Company’s named executive officers:

Votes For

Votes Against

Votes Abstaining

Broker Non-Votes

4,206,592

472,820

30,926

5,420,186

3.Ratification of the selection of Mayer Hoffman McCann PC as independent registered public accounting firm for the year ending December 31, 2015:

Votes For

Votes Against

Votes Abstaining

 

9,654,513

18,972

457,039

 

 


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ADAMIS PHARMACEUTICALS CORPORATION

 

 

 

 

Dated:   May 19, 2015

 

By:

/s/ Robert O. Hopkins

 

 

 

Name:  Robert O. Hopkins

 

 

 

Title:  Chief Financial Officer